Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acadia Pharmaceuticals Inc.
< Previous
1
2
3
Next >
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
November 30, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
November 27, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
November 21, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
November 02, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
October 31, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
October 23, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
October 19, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
September 19, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 30, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
August 02, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
July 24, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
July 19, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
July 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
June 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
June 08, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
May 08, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 02, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
April 25, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 20, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
April 17, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
March 10, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.